CN110214152B - 模块化四聚体双特异性抗体平台 - Google Patents
模块化四聚体双特异性抗体平台 Download PDFInfo
- Publication number
- CN110214152B CN110214152B CN201780067582.7A CN201780067582A CN110214152B CN 110214152 B CN110214152 B CN 110214152B CN 201780067582 A CN201780067582 A CN 201780067582A CN 110214152 B CN110214152 B CN 110214152B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdrs
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510732184.9A CN120795163A (zh) | 2016-10-14 | 2017-10-16 | 模块化四聚体双特异性抗体平台 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408271P | 2016-10-14 | 2016-10-14 | |
| US62/408,271 | 2016-10-14 | ||
| PCT/US2017/056814 WO2018071913A2 (en) | 2016-10-14 | 2017-10-16 | Modular tetrameric bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510732184.9A Division CN120795163A (zh) | 2016-10-14 | 2017-10-16 | 模块化四聚体双特异性抗体平台 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110214152A CN110214152A (zh) | 2019-09-06 |
| CN110214152B true CN110214152B (zh) | 2025-06-13 |
Family
ID=60327374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780067582.7A Active CN110214152B (zh) | 2016-10-14 | 2017-10-16 | 模块化四聚体双特异性抗体平台 |
| CN202510732184.9A Pending CN120795163A (zh) | 2016-10-14 | 2017-10-16 | 模块化四聚体双特异性抗体平台 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510732184.9A Pending CN120795163A (zh) | 2016-10-14 | 2017-10-16 | 模块化四聚体双特异性抗体平台 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200017588A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3526257A2 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7269167B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110214152B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017341936B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3038504A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018071913A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| WO2018145075A1 (en) * | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业(上海)股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| AU2023232045A1 (en) | 2022-03-09 | 2024-09-26 | Dana-Farber Cancer Institute, Inc. | Genetically engineered b cells and methods of use thereof |
| CA3263665A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anti-CLDN4 antibodies and their methods of use |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| CN121399164A (zh) * | 2023-06-20 | 2026-01-23 | 戴纳立制药公司 | 双重转运体及使用方法 |
| WO2026117666A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Bispecific antibodies for treating cancer |
| WO2026117664A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Engineered cells and uses thereof for treating cancer |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943740B2 (en) * | 2003-12-05 | 2011-05-17 | Multimmune Gmbh | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| US8084026B2 (en) * | 2005-01-05 | 2011-12-27 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| CA3099509A1 (en) * | 2011-07-07 | 2013-01-10 | Centre National De La Recherche Scientifique | Multispecific antibodies |
| WO2013096346A1 (en) * | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| WO2015187835A2 (en) * | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| CN105492463A (zh) * | 2013-08-20 | 2016-04-13 | 默沙东公司 | 肿瘤免疫调节 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN1914226B (zh) | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| JP2011524966A (ja) * | 2008-02-22 | 2011-09-08 | ダウ グローバル テクノロジーズ エルエルシー | 熱エネルギー貯蔵材料 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| EP2794662A1 (en) * | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| EP2850106B1 (en) * | 2012-05-18 | 2022-03-23 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP2920210B1 (en) * | 2012-11-19 | 2017-08-30 | Baliopharm AG | Recombinant bispecific antibody binding to cd20 and cd95 |
| CN105530959B (zh) | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| EP4292657A3 (en) | 2013-03-15 | 2024-03-20 | Dana Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| KR20160122127A (ko) * | 2013-12-23 | 2016-10-21 | 자임워크스 인코포레이티드 | C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법 |
| EP3119804A2 (en) | 2014-03-19 | 2017-01-25 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| WO2015164865A1 (en) | 2014-04-25 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| CA2962949C (en) | 2014-10-06 | 2024-03-05 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| US11135282B2 (en) | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| JP7649239B2 (ja) * | 2018-11-30 | 2025-03-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | キメラ抗原受容体ファクトリおよびその使用方法 |
-
2017
- 2017-10-16 EP EP17798026.5A patent/EP3526257A2/en active Pending
- 2017-10-16 US US16/340,878 patent/US20200017588A1/en not_active Abandoned
- 2017-10-16 JP JP2019520024A patent/JP7269167B2/ja active Active
- 2017-10-16 CN CN201780067582.7A patent/CN110214152B/zh active Active
- 2017-10-16 CA CA3038504A patent/CA3038504A1/en active Pending
- 2017-10-16 CN CN202510732184.9A patent/CN120795163A/zh active Pending
- 2017-10-16 AU AU2017341936A patent/AU2017341936B2/en active Active
- 2017-10-16 WO PCT/US2017/056814 patent/WO2018071913A2/en not_active Ceased
-
2023
- 2023-04-21 JP JP2023069848A patent/JP7796079B2/ja active Active
-
2025
- 2025-01-31 AU AU2025200665A patent/AU2025200665A1/en active Pending
- 2025-07-16 JP JP2025119440A patent/JP2025142045A/ja active Pending
- 2025-09-03 US US19/318,009 patent/US20260193357A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943740B2 (en) * | 2003-12-05 | 2011-05-17 | Multimmune Gmbh | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| US8084026B2 (en) * | 2005-01-05 | 2011-12-27 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| CA3099509A1 (en) * | 2011-07-07 | 2013-01-10 | Centre National De La Recherche Scientifique | Multispecific antibodies |
| WO2013096346A1 (en) * | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| CN105492463A (zh) * | 2013-08-20 | 2016-04-13 | 默沙东公司 | 肿瘤免疫调节 |
| WO2015187835A2 (en) * | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| "A dimeric bispecific miniantibody combines two specificities with avidity";Kristian M.Müller et al.,;《FEBS Letters》;19980731;第432卷(第1-2期);第45-49页 * |
| Kristian M. Müller et al.,."A dimeric bispecific miniantibody combines two specificities with avidity".《FEBS Letters》.1998,第432卷(第1-2期),图1和第47页左栏第1段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019533675A (ja) | 2019-11-21 |
| CN110214152A (zh) | 2019-09-06 |
| EP3526257A2 (en) | 2019-08-21 |
| AU2025200665A1 (en) | 2025-04-10 |
| US20260193357A1 (en) | 2026-07-09 |
| JP7269167B2 (ja) | 2023-05-08 |
| CN120795163A (zh) | 2025-10-17 |
| WO2018071913A2 (en) | 2018-04-19 |
| US20200017588A1 (en) | 2020-01-16 |
| JP2023093642A (ja) | 2023-07-04 |
| WO2018071913A3 (en) | 2018-05-24 |
| AU2017341936A1 (en) | 2019-04-04 |
| JP2025142045A (ja) | 2025-09-29 |
| JP7796079B2 (ja) | 2026-01-08 |
| CA3038504A1 (en) | 2018-04-19 |
| AU2017341936B2 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN120795163A (zh) | 模块化四聚体双特异性抗体平台 | |
| KR102924006B1 (ko) | 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도 | |
| US10889652B2 (en) | Antibodies and chimeric antigen receptors specific for ROR1 | |
| JP7305538B2 (ja) | 細胞によって発現される生物活性を調節する結合分子 | |
| KR20210122272A (ko) | 수용체 티로신 키나제 유사 고아 수용체 1(ror1)에 특이적인 항체 및 키메라 항원 수용체 | |
| AU2018360800A1 (en) | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) | |
| JP2022516809A (ja) | 抗cld18a2ナノ抗体及びその応用 | |
| CN112639102A (zh) | 抗间皮素嵌合抗原受体(car)构建体及其用途 | |
| JP7862562B2 (ja) | アゴニストltbr抗体及びそれらを含む二重特異性抗体 | |
| JP7462611B2 (ja) | Ox40結合性ポリペプチド及びその使用 | |
| AU2017233658A1 (en) | Cell injury inducing therapeutic drug for use in cancer therapy | |
| BRPI0611194B1 (pt) | Moléculas de ligação anti-cd16 | |
| JP2021502360A (ja) | 二重特異的融合ポリペプチド及びその使用方法 | |
| JP7584453B2 (ja) | Taciを標的とする抗体及びキメラ抗原受容体 | |
| TW202216745A (zh) | 包含經修飾il-2多肽之多肽及其用途 | |
| KR102412805B1 (ko) | 세포 면역 요법을 위한 조성물 및 방법 | |
| CN111848809A (zh) | 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途 | |
| CN116249559A (zh) | 抗独特型组合物及其使用方法 | |
| CN116964100A (zh) | Gucy2c结合多肽及其用途 | |
| JP2026513651A (ja) | Adgre2キメラ受容体nk細胞組成物及び使用方法 | |
| US20260028402A1 (en) | Anti-cd100 antibody and use thereof | |
| TW202435913A (zh) | 針對血癌之抗體 | |
| HK40103535A (en) | Binding molecules that modulate a biological activity expressed by a cell | |
| HK40010370A (en) | Tri-chain antibody, preparation method and use thereof | |
| HK40041676A (en) | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |